Search
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966] … hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with cardiovascular risk, and it was these observations that provided a rationale for
Sodium sulfate
go.drugbank.com/drugs/DB09472ApprovedInvestigationalVet approvedSodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and play...
Mixtures: FORTRANS FOR ORAL SOLUTIONCategories: Drugs for ConstipationTebipenem pivoxil
go.drugbank.com/drugs/DB16840Approved[L57980] Tebipenem pivoxil is the first oral carbapenem approved in the United States, creating an outpatient option for patients who have limited or no alternative oral therapy. … [L57979] Carbapenems are the standard treatment for severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseAmantadine
go.drugbank.com/drugs/DB00915ApprovedInvestigationalIt is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia.
Docusate
go.drugbank.com/drugs/DB11089ApprovedDocusate, or dioctyl sulfosuccinate, is a stool softener indicated for the treatment of constipation[A32201]. … However the effectiveness of docusate in treating constipation remains unclear, as several studies report docusate to be no more effective than placebo for increasing the frequency of stool or stool softening
Categories: Drugs for ConstipationSulfamerazine
go.drugbank.com/drugs/DB01581ApprovedVet approvedWithdrawnA sulfanilamide that is used as an antibacterial agent.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseDoxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational, while the existing tablet formulation remains indicated for patients aged six years and older. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and